Get the Stockscreener App
0.56
0.36%
-0.002
After Hours:
.56
Mustang Bio Inc stock is traded at $0.56, with a volume of 7,855.
It is down -0.36% in the last 24 hours and down -20.38% over the past month.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
See More
Previous Close:
$0.562
Open:
$0.57
24h Volume:
7,855
Relative Volume:
0.07
Market Cap:
$4.24M
Revenue:
-
Net Income/Loss:
$-2.72M
P/E Ratio:
-1.1664
EPS:
-0.4801
Net Cash Flow:
$-4.88M
1W Performance:
-14.11%
1M Performance:
-20.38%
6M Performance:
-45.10%
1Y Performance:
-70.68%
1-Day Range:
$0.56
$0.5735
1-Week Range:
$0.56
$0.63
52-Week Range:
$0.5306
$1.96
Mustang Bio Inc Stock (MBIO) Company Profile
Name
Mustang Bio Inc
Sector
Industry
Phone
(781) 652-4500
Address
95 SAWYER RD, WALTHAM, NY
Compare MBIO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBIO
Mustang Bio Inc
|
0.56 | 4.26M | 0 | -2.72M | -4.88M | -0.4801 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-21 | Initiated | BTIG Research | Buy |
| Oct-02-20 | Initiated | B. Riley FBR | Buy |
| Nov-20-19 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-19 | Initiated | H.C. Wainwright | Buy |
| Jun-21-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Initiated | Oppenheimer | Outperform |
View All
Mustang Bio Inc Stock (MBIO) Latest News
Mustang Bio Inc (MBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mustang Bio, Inc. Revenue Breakdown – NASDAQ:MBIO - TradingView
Mustang Bio Inc (MBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
MBIO|Mustang Bio Inc|Price:0.579|Chg%:+0.009 - TradingKey
Mustang Bio Inc (MBIO) Institutional Confidence - TradingKey
Frontier tech research, news & data - MLQ.ai
Car T Cell Therapy Market Set to Booming Growth 2026-2033 | Novartis AG, Gilead Sciences, Inc - EIN News
Mustang Bio stock trades lower as cash runway and trial update shape outlook - Ad-hoc-news.de
MSN Money - MSN
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Significant EPS Miss Amidst Ongoing Operational ChallengesPost-Earnings Reaction - dars.gov.et
Americore Resources Appoints Justin Hanka to Its Board of Directors - Moomoo
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Deep Losses Overshadow Progress in CAR T PipelineGuidance Update - DonanımHaber
Mustang Bio (MBIO) Q1 2026 earnings summary - Quartr
Mustang Bio (MBIO) Proxy Filing Summary - Quartr
Mustang Bio (MBIO) Registration Filing Summary - Quartr
TDW Q1 2026 Earnings: Significant EPS Miss Despite Stock GainDebt Analysis Report - dars.gov.et
MBIO Should I Buy - Intellectia AI
MBIO Q4 2024 Earnings: Massive EPS Miss as Clinical-Stage Biotech Reports No RevenueEarnings Revision Report - dars.gov.et
Enterprise value to EBIT forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Enterprise value to EBITDA forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Enterprise value to EBIT forward of Mustang Bio, Inc. – BOATS:MBIO - TradingView
Price to earnings forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Price to book forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Price to earnings forward of Mustang Bio, Inc. – BOATS:MBIO - TradingView
Enterprise value to revenue forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Price to sales forward of Mustang Bio, Inc. – NASDAQ:MBIO - TradingView
Price to sales forward of Mustang Bio, Inc. – BOATS:MBIO - TradingView
Traders are paying attention to the gapping stocks in Friday's session. - ChartMill
Mustang Bio Inc (MBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mustang Bio, Inc. Actuals & Estimates (NASDAQ:MBIO) - TradingView
MBIO Q4 2024 Earnings: Massive EPS Miss as Pre-Revenue Biotech Faces Cash Burn ChallengesGAAP Earnings Report - Bölüm Sonu Canavarı
Silver Tiger Metals Inc.'s (TSE:SLVR) Path To Profitability - simplywall.st
Mustang Bio Inc. (MBIO) Edges Higher Amid Tight Trading Range: Key Levels in FocusFast Moving Stocks - dars.gov.et
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: Significant EPS Miss Reflects Ongoing Clinical-Stage Challenges - dars.gov.et
MBIO Q4 2024 Earnings: Wider-than-Expected Loss Amid Clinical ProgressGuidance Revision Trend - dars.gov.et
Glioma Pipeline Insights Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
EQR Q1 2026 Earnings: EPS Misses Estimates, Stock Edges LowerStrong Earnings Momentum - dars.gov.et
Mustang Bio Inc (MBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mustang Bio Inc (MBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mustang Bio Inc (MBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mustang Bio Inc (MBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mustang Bio Inc (MBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SpaceX IPO Leaves Retail Investors Scrambling as Tiny Allocations Spur Mixed ReactionsBuyback Announcement Report - newsline.com
CNET Q3 2011 Earnings: EPS Misses by 65.4% Amid Uncertain Revenue DisclosureEarnings Growth Analysis - newsline.com
Getty Images Holdings (GETY) Slides 2.55% as Stock Nears Key Support at $0.70VWAP Breakout - newsline.com
MBIO Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Mustang Bio Inc. (MBIO) Q4 2024 Earnings: EPS Misses by Wide Margin Amid No Revenue; Stock DeclinesDownward Estimate Revision - dars.gov.et
ADXN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
American Airlines (AAL) Q1 2026 Earnings: EPS Beats Estimates Despite Net LossHealthcare Earnings Report - dars.gov.et
MBIO Q4 2024 Earnings: Substantial EPS Miss Reflects Clinical-Stage Development CostsFull Year Guidance - dars.gov.et
Mustang Bio Inc Stock (MBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):